Kymera Therapeutics Presents New Preclinical Data for – GlobeNewswire
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual …
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual …
(NASDAQ: TNXP) presented clinical trial data for its fibromyalgia treatment Tonmya at the 2025 American College of Rheumatology Convergence in
… Rheumatology (ACR) Convergence, held October 24–29, 2025, in Chicago … Rheumatology criteria for fibromyalgia. Treatment with Tonmya …
Kymera Therapeutics (NASDAQ: KYMR) presented new preclinical data for KT-579, an oral IRF5 degrader, at the American College of Rheumatology
The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product,
We collected audit data from patients aged 16 years and older who attended specialist rheumatology centres in England and Wales
… Rheumatology (ACR) Convergence 2025, currently underway in Chicago. The featured poster highlights findings from Citryll’s Phase I clinical trial …
Hospitals and specialized rheumatology centers provide improved access to clinical care, which strengthens treatment uptake across the region. In …
For rheumatologists, these data reinforce upadacitinib’s role as a viable and durable option for patients across multiple lines of therapy,
claire-daien-md-phd. Advertisement. Claire Daien, MD, PhD. Prof of Rheumatology at Université de Montpellier. Articles by Claire Daien, MD, PhD …
Upadacitinib is a Double Edged Vascular Sword in GCA tammytilley@gm… Sun, 10/26/2025 – 23:41 Education/ACR/EULAR Anti-Rheumatic Rx Labs/Biomarkers Steroids Vasculitis
#ACR25 Abstr#0773 Anti-MDA5 ab is assoc. with progressive DM-ILD. But MDA5 expression is also upregulated in IPF. Any ne https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg
What is the #frequency of #CTD #ILD in #USA? Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts 56-65 yrs,
Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMb https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john… Sun, 10/26/2025
AI Scribes Found their Favorite Doctors tammytilley@gm… Sun, 10/26/2025 – 20:53 Education/ACR/EULAR General Rheumatology Dr. Aurelie Najm discusses abstract 0189,
Next Generation T-Cell Engager: The Future tammytilley@gm… Sun, 10/26/2025 – 19:29 Education/ACR/EULAR Novel Rx Dr. Alfred Kim reviews abstract 0001
High prevalence of sleep related symptoms in PsA pts! -Snoring 53% -Morning fatigue 68% -Obstructive Sleep Apnea in https://pbs.twimg.com/profile_images/1800478984926334976/yyyPLP4A_normal.jpg john+RNV2@john…
#ACR25 Abstr#663 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 8 #SLE patients in Phase 1. Ad https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg john+RNV2@john…
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE tammytilley@gm… Sun, 10/26/2025 – 19:09 Lupus Novel Rx Steroids Dr. Sheila
ACR25 Best Abstracts – Day 1 jjcush@gmail.com Sun, 10/26/2025 – 19:00
Dr. Ogdie on emerging PsA tx: “It’s not just about the pharmacotherapy but also about making the patient feel bette
Why do we need to identify early PsA? 🔅Improve symptoms 🔅Prevent radiographic progression 🔅Preserve function ? https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg john+RNV2@john… Sun, 10/26/2025
What are the RFs for progression of Pso to PsA? 🔸PsO disease severity – 3.2x risk —>PsA 🔸Phenotype – nail
The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWAC https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john… Sun, 10/26/2025
We’ll explore how SPY072’s differentiated dosing profile could influence Spyre Therapeutics’ place in the competitive rheumatology pipeline. Rare …
ACR2025 Day 1 RECAP https://t.co/zARgu7vx3m https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Sun, 10/26/2025 – 18:01 RheumNow Dr. John Cush ACR2025 Day 1 RECAP https://t.co/zARgu7vx3m